New GEMMs are needed in order to explore targetable somatic mutations found in human meningiomas, such as TRAF7, AKT1 or PIK3CA, where they will be essential for understanding the specific biological mechanisms involved and to provide accurate tools for preclinical drug evaluation. This evidence concerns the gene AKT1 and meningioma.